CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biomarin Pharmaceutical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biomarin Pharmaceutical Inc
105 Digital Dr
Phone: (415) 506-6700p:415 506-6700 NOVATO, CA  94949-8703  United States Ticker: BMRNBMRN

Business Summary
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Richard A.Meier 64 12/1/2023 12/14/2006
President, Chief Executive Officer, Director AlexanderHardy 55 12/1/2023 12/1/2023
Chief Financial Officer, Executive Vice President - Finance Brian R.Mueller 49 6/29/2020 3/1/2011
15 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BIOMARIN (U.K.) LTD. 10 BLOOMSBURY WAY LONDON UK
BIOMARIN EUROPE LIMITED 6TH FLOOR 2 GRAND CANAL SQUARE DUBLIN 2 IE
BIOMARIN COMMERCIAL LIMITED 6TH FLOOR 2 GRAND CANAL SQUARE DUBLIN 2DUBLIN IE
5 additional Subsidiary records available in full report.

Business Names
Business Name
BIOMARIN (U.K.) LTD.
BioMarin Commercial Ltd
BioMarin Deutschland GmbH
7 additional Business Names available in full report.

General Information
Number of Employees: 3,401 (As of 12/31/2023)
Outstanding Shares: 188,675,622 (As of 2/16/2024)
Shareholders: 34
Stock Exchange: NASD
Federal Tax Id: 680397820
Fax Number: (415) 382-7889
Email Address: CorporateCommunications2@bmrn.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024